SCHEMBL3109670

SCHEMBL3109670

CC(Oc1ccc([N+](=O)[O-])cc1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MET P08581 13/20 0.50
KDR P35968 6/20 0.50
SRC P12931 3/20 0.50
FGFR2 P21802 2/20 0.50
AXL P30530 2/20 0.50
FLT3 P36888 2/20 0.50
MST1R Q04912 2/20 0.50
KIT P10721 1/20 0.50
INPPL1 O15357 7/20 0.46
AURKA O14965 1/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
YES1 P07947 1/20 0.44
EPHA2 P29317 1/20 0.44
LTK P29376 1/20 0.44
PTK6 Q13882 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3099307 0.90 HSPB1 (0.41) METKDRSRCFGFR2AXL
SCHEMBL3099647 0.89 LMNA (0.44) METKDRSRCFGFR2AXL
SCHEMBL3104563 0.88 HSPB1 (0.42) METKDRSRCFGFR2AXL
SCHEMBL3102150 0.84 MET (0.48) METKDRSRCFGFR2AXL
SCHEMBL3111405 0.84 MET (0.48) METKDRSRCFGFR2AXL
SCHEMBL3093192 0.84 MET (0.53) METKDRSRCFGFR2AXL
SCHEMBL3104388 0.83 MET (0.50) METKDRSRCFGFR2AXL
SCHEMBL3102498 0.83 HSPB1 (0.40) METKDRSRCFGFR2AXL
SCHEMBL3097938 0.82 MET (0.47) METKDRSRCFGFR2AXL
SCHEMBL3094219 0.81 HSPB1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
CN-101827827-A Derivatives of 6-aryl/heteroalkoxybenzothiazoles and benzimidazoles, method for preparing same, use thereof as medicaments, pharmaceutical compositions and novel use thereof, in particular as CMET inhibitors SANOFI AVENTIS 2010-09-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 MET 1/4885KDR 41/4885SRC 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.